Experimental drug for early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests an experimental drug called RO7568282 for people in the early stages of Alzheimer's disease. The goal is to see if it is safe and whether it can slow down memory loss and thinking problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a diagnosis of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease.
- Show evidence of Alzheimer's disease through a PET brain scan or a spinal fluid test.
- Be able to swallow large capsules (pills) whole.
- Have a study partner (a friend or family member) who can come to appointments and help you.
- Have a body mass index (BMI) between 18 and 34, which is within a healthy to moderately overweight range for most adults.
- Not have other conditions that could explain memory problems, such as significant heart disease, blood vessel disease in the brain, or major brain abnormalities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial tests a new drug, NBI-1117567, for people with mild to moderate Alzheimer's disease who are already taking a standard Alzheimer's medication. The goal is to see if the new drug can help improve symptoms.
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
This trial tests an experimental drug, ARO-MAPT-SC, which may slow the progression of early Alzheimer's disease by targeting a protein involved in the disease. It is given as an injection under the skin and is being studied in healthy people and those with early Alzheimer's.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.